MK-1022, -, MK-1084, MK-1084, MK-2870, MK-1084, CETUXIMAB , MK-1084
MK-3475-01F
Phase 2 small_molecule active
Quick answer
MK-1022, -, MK-1084, MK-1084, MK-2870, MK-1084, CETUXIMAB , MK-1084 for Non-small Cell Lung Cancer (NSCLC) is a Phase 2 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Merck Sharp and Dohme
- Indication
- Non-small Cell Lung Cancer (NSCLC)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active